HomeGeneticsConditionCombined pituitary hormone deficiency
Back to Condition
Combined pituitary hormone deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Combined pituitary hormone deficiency

Combined pituitary hormone deficiency (CPHD) involves the partial or complete loss of two or more hormones produced by the pituitary gland, impacting growth and development.

Overview

Combined pituitary hormone deficiency is a condition that causes a partial or complete loss of two or more hormones produced by the pituitary gland. The pituitary gland produces hormones essential for growth, sexual development, energy use, and stress response.

Symptoms

Symptoms depend on the specific hormones involved but often include:

  • Short stature and growth failure in early childhood.
  • Infants may exhibit jaundice, hypoglycemia, and genital abnormalities.
  • Fatigue, weight changes, delayed or absent puberty, and fertility problems.
  • Craniofacial abnormalities, brain abnormalities, seizures, developmental delays, and eye disorders like optic nerve hypoplasia.

Causes

Congenital CPHD is often caused by variants in genes (such as PROP1) that provide instructions for transcription factors, which control pituitary gland development and cell specialization. Acquired CPHD is caused by later-life factors such as brain damage, tumors, medications, infections, or autoimmune disorders.

Inheritance

Congenital CPHD can be inherited in an autosomal dominant or autosomal recessive pattern. It can also be inherited in an X-linked pattern. Some cases result from new (de novo) variants. Acquired CPHD is not inherited.

Frequently Asked Questions

Yes, these are red‑flag signs. An endocrinologist will order a basal hormone panel (GH, ACTH, TSH, LH/FSH, prolactin) plus stimulation tests (e.g., insulin tolerance test) and obtain MRI of the sellar region to assess pituitary size and structure.
dminister immediate IV hydrocortisone 100 mg (or 50 mg if <30 kg), give isotonic saline bolus for hypotension, monitor glucose and electrolytes, and treat underlying triggers; then transition to a maintenance glucocorticoid regimen once stable.
Hormone panels should be checked at least annually, with more frequent assessments (every 3–6 months) during periods of rapid growth, puberty onset, or when new symptoms arise, to adjust replacement therapy promptly.
Yes, with appropriate sex‑steroid replacement (testosterone for males, estrogen + progesterone for females) and, if gonadotropin deficiency persists, recombinant LH/FSH therapy can induce spermatogenesis or ovulation; fertility counseling and assisted reproductive techniques may also be considered.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss